• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday

    6/28/24 9:17:32 AM ET
    $CRL
    $INFN
    $NKE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Telecommunications Equipment
    Utilities
    Get the next $CRL alert in real time by email

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

    • JP Morgan analyst Matthew Boss downgraded NIKE, Inc. (NYSE:NKE) from Overweight to Neutral, while cutting the price target from $116 to $83. Nike shares gained 0.1% to close at $94.19 on Thursday. See how other analysts view this stock.
    • Argus Research analyst David Toung downgraded the rating for Charles River Laboratories International, Inc. (NYSE:CRL) from Buy to Hold. Charles River shares gained 0.3% to close at $207.35 on Thursday. See how other analysts view this stock.
    • Stifel analyst Jim Duffy downgraded the rating for NIKE, Inc. (NYSE:NKE) from Buy to Hold and slashed the price target from $117 to $88. Nike shares gained 0.1% to close at $94.19 on Thursday. See how other analysts view this stock.
    • Needham analyst Ryan Koontz downgraded Infinera Corporation (NASDAQ:INFN) from Buy to Hold. Infinera shares rose 1.5% to settle at $5.26 on Thursday. See how other analysts view this stock. See how other analysts view this stock.
    • Morgan Stanley analyst Alex Straton downgraded NIKE, Inc. (NYSE:NKE) from Overweight to Equal-Weight, while lowering the price target from $114 to $79. Nike shares gained 0.1% to close at $94.19 on Thursday.  See how other analysts view this stock.

    Check This Out: Top 3 Real Estate Stocks You’ll Regret Missing In June

    Get the next $CRL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRL
    $INFN
    $NKE

    CompanyDatePrice TargetRatingAnalyst
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    Nike Inc.
    $NKE
    12/19/2025$75.00 → $72.00Market Perform
    Telsey Advisory Group
    Nike Inc.
    $NKE
    12/19/2025$78.00 → $68.00Buy
    Needham
    Charles River Laboratories International Inc.
    $CRL
    12/15/2025$225.00Neutral → Buy
    BofA Securities
    Nike Inc.
    $NKE
    12/10/2025$77.00Buy
    Guggenheim
    Charles River Laboratories International Inc.
    $CRL
    11/17/2025Hold → Buy
    Argus
    Nike Inc.
    $NKE
    11/13/2025$75.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $CRL
    $INFN
    $NKE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on NIKE

    Deutsche Bank initiated coverage of NIKE with a rating of Hold

    1/8/26 10:59:22 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE downgraded by Needham

    Needham downgraded NIKE from Buy to Hold

    1/8/26 8:41:20 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on NIKE with a new price target

    Telsey Advisory Group reiterated coverage of NIKE with a rating of Market Perform and set a new price target of $72.00 from $75.00 previously

    12/19/25 7:55:36 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $CRL
    $INFN
    $NKE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Swan Robert Holmes bought $500,080 worth of Class B Common Stock (8,691 units at $57.54), increasing direct ownership by 25% to 43,293 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:21:15 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $CRL
    $INFN
    $NKE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charles River Laboratories Announces Executive Appointments

    Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre

    2/18/26 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    – Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm

    2/18/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $CRL
    $INFN
    $NKE
    SEC Filings

    View All

    Charles River Laboratories International Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    2/18/26 4:39:47 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by Charles River Laboratories International Inc.

    10-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    2/18/26 9:21:09 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    2/18/26 7:13:34 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    $INFN
    $NKE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP: Chief Legal Officer Leinwand Robert sold $565,021 worth of Class B Common Stock (9,065 units at $62.33), decreasing direct ownership by 13% to 61,662 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/13/26 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Chairman Emeritus Knight Philip H gifted 4,500,000 units of Class B Common Stock and received a gift of 4,500,000 units of Class B Common Stock, decreasing direct ownership by 35% to 8,335,687 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/13/26 4:23:29 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    EVP: Chief Legal Officer Leinwand Robert covered exercise/tax liability with 4,647 units of Class B Common Stock, decreasing direct ownership by 6% to 70,727 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    2/12/26 4:16:13 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $CRL
    $INFN
    $NKE
    Leadership Updates

    Live Leadership Updates

    View All

    Charles River Laboratories Announces Executive Appointments

    Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre

    2/18/26 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Vuori Appoints Andrew Campion to Board of Directors

    The addition of the industry leader reinforces the brand's continued momentum and further fuels its strategic growth priorities Vuori, the performance and lifestyle brand known for its coastal California-inspired style, today announced the appointment of Andrew Campion to its Board of Directors and a member of its Audit Committee. For over 17 years, Andy served in executive leadership roles at Nike Inc. (NYSE:NKE), including as Chief Operating Officer, Chief Financial Officer, and head of global strategy. Prior to Nike, Campion was with The Walt Disney Company (NYSE:DIS), serving as its Senior Vice President of Corporate Development. Currently, Andy is the Chairman and CEO of Unrivaled

    9/15/25 6:00:00 AM ET
    $DIS
    $NKE
    $SBUX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Shoe Manufacturing
    Restaurants

    Jørgen Vig Knudstorp Nominated to Join NIKE, Inc. Board of Directors

    NIKE, Inc. (NYSE:NKE) today announced Jørgen Vig Knudstorp has been nominated for election to its Board of Directors at the Company's 2025 annual meeting of shareholders, to be held on September 9, 2025. Mr. Knudstorp was President and Chief Executive Officer of the LEGO Group ("LEGO") from 2004 to 2016, Executive Chair of LEGO Brand Group from 2017 to 2023 and currently serves as Deputy Chair of the LEGO Foundation. He previously held various leadership positions at LEGO from 2001 to 2004. "Jørgen's strong global experience with brand and digital marketing, strategy, and consumer products, as well as his development and fostering of culture and values, will make him an excellent additi

    6/24/25 4:15:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $CRL
    $INFN
    $NKE
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    – Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm

    2/18/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NIKE, Inc. Declares $0.41 Quarterly Dividend

    NIKE, Inc. (NYSE:NKE) announced today that its Board of Directors has declared a quarterly cash dividend of $0.41 per share on the Company's outstanding Class A and Class B Common Stock payable on April 1, 2026, to shareholders of record at the close of business on March 2, 2026. About NIKE, Inc. NIKE, Inc., headquartered near Beaverton, Oregon, is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly-owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE,

    2/13/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi

    1/21/26 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    $INFN
    $NKE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Charles River Laboratories International Inc.

    SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    11/8/24 10:52:38 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    10/22/24 3:24:03 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by Infinera Corporation

    SC 13G - Infinera Corp (0001138639) (Subject)

    10/7/24 4:44:52 PM ET
    $INFN
    Telecommunications Equipment
    Utilities